Cashflow Stability Model

📈 Cashflow Stability Model — when can the owner draw a salary?

Question: how many cycles (months) until Indexa can sustainably pay the founder RM1,200–2,000/month without hurting its ability to restock and grow?

Answer: ~3 cycles on the numbers — gated by the loan, not by profit

The surprising result: your economics already support the salary today. With ~70% gross margins and only ~RM28/month fixed cost, the business throws off ~RM2,600/month of surplus (after replacing sold stock and funding growth) — already more than a RM2,000 salary. The only thing in the way is housekeeping:

1. Repay the RM4,230 founder loan — 3 months at RM2,000/mo as stock.
2. Hold a ~RM5,000 buffer so one slow month never blocks a restock.

Both clear by ~cycle 3, after which RM1,200–2,000/month is mathematically safe — and the result is the same whether sales grow 0% or 20% a month, because the margin is doing the work.

Growth / mo	RM1,200 safe at	RM2,000 safe at
0% (flat, Muz only)	cycle 3	cycle 3
12%	cycle 3	cycle 3
20%	cycle 3	cycle 3

Model: revenue RM4,300/mo, 67% margin, RM50 fixed, founder repays RM2k/mo, buffer target RM5k.

⚠️ But the real gate is RISK, not profit

The model is robust to growth but not to demand collapse — and Muz is 93% of revenue. That RM4,300/month is one person deep. Drawing a salary on top of a single-customer income is the actual danger, not the math.

So the prudent timeline:

Cycle	Milestone
1–2	Founder repays loan (as stock). Restock Reta 60mg + 20mg + GHK. Buffer starts.
2–3	Loan cleared. Buffer ≈ RM5k. Add a 2nd & 3rd active reseller so no one is >50% of sales.
3–4	Start RM1,200/month salary. Keep reinvesting the rest into stock + a new peptide line.
5–6	Revenue de-risked & past ~RM6–7k/mo → step to RM2,000/month, still funding growth.

Bottom line: ~3 cycles to afford it, ~5–6 cycles to safely take it — the extra 2–3 cycles buy down the Muz single-point-of-failure. This is Stage 3 of the Mission & Policies ladder; the de-risking is Stage 1’s “≥4 active resellers” exit condition doing its job.

Why the engine is this strong

• Margins: Reta 60mg 71% dropship / 89% public · Reta 20mg 71% / 86% · GHK-Cu 76%.
• Fixed cost ≈ RM28/mo (Lovable + domain). Everything else is per-batch (stock + ~RM240 COA) or per-order (RM15 ship).
• So almost every ringgit of margin is free cash — the business compounds fast if demand keeps up. Demand (resellers, lines, channels) is the throttle, not money.

To go faster — and toward the "one-stop peptide shop"

Each reinvested cycle should do two jobs: deepen the proven sellers (Reta) and widen the catalogue (add 1 new TCI line per cycle — the price lists already have 30+ options). Widening is what turns a 1-product, 1-reseller business into a destination — and it’s what makes the salary safe, because revenue stops depending on Muz + Reta alone.

Related

• Stock & Revenue Reconciliation (the real numbers this is built on) · Mission & Policies (stage ladder) · Restock Plan — 2026-06 · Pricing Model